A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma

Trial Profile

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; IMC gp100 (Primary) ; Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Immunocore
  • Most Recent Events

    • 12 Apr 2017 Planned number of patients changed from 224 to 225.
    • 12 Apr 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 20 Jan 2016 Status changed from not yet recruiting to recruiting, as reported in an Immunocore media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top